271 related articles for article (PubMed ID: 35885657)
1. Simultaneously Screening for Liver Steatosis and Fibrosis in Romanian Type 2 Diabetes Mellitus Patients Using Vibration-Controlled Transient Elastography with Controlled Attenuation Parameter.
Trifan A; Stratina E; Nastasa R; Rotaru A; Stafie R; Zenovia S; Huiban L; Sfarti C; Cojocariu C; Cuciureanu T; Muzica C; Chiriac S; Girleanu I; Singeap AM; Stanciu C
Diagnostics (Basel); 2022 Jul; 12(7):. PubMed ID: 35885657
[TBL] [Abstract][Full Text] [Related]
2. The Prevalence of Liver Steatosis and Fibrosis Assessed by Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter in Apparently Healthy Romanian Medical Students.
Nastasa R; Stanciu C; Zenovia S; Singeap AM; Cojocariu C; Sfarti C; Girleanu I; Chiriac S; Cuciureanu T; Huiban L; Muzica CM; Trifan A
Diagnostics (Basel); 2021 Dec; 11(12):. PubMed ID: 34943578
[TBL] [Abstract][Full Text] [Related]
3. Screening for Liver Fibrosis and Steatosis in a Large Cohort of Patients with Type 2 Diabetes Using Vibration Controlled Transient Elastography and Controlled Attenuation Parameter in a Single-Center Real-Life Experience.
Sporea I; Mare R; Popescu A; Nistorescu S; Baldea V; Sirli R; Braha A; Sima A; Timar R; Lupusoru R
J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32268517
[TBL] [Abstract][Full Text] [Related]
4. Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter for the Diagnosis of Liver Steatosis and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease.
Zenovia S; Stanciu C; Sfarti C; Singeap AM; Cojocariu C; Girleanu I; Dimache M; Chiriac S; Muzica CM; Nastasa R; Huiban L; Cuciureanu T; Trifan A
Diagnostics (Basel); 2021 Apr; 11(5):. PubMed ID: 33925569
[TBL] [Abstract][Full Text] [Related]
5. Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: A transient elastography study.
Demir M; Deyneli O; Yılmaz Y
Turk J Gastroenterol; 2019 Mar; 30(3):266-270. PubMed ID: 30411703
[TBL] [Abstract][Full Text] [Related]
6. Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Cao YT; Xiang LL; Qi F; Zhang YJ; Chen Y; Zhou XQ
EClinicalMedicine; 2022 Sep; 51():101547. PubMed ID: 35844772
[TBL] [Abstract][Full Text] [Related]
7. Transient elastography for the prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes: Evidence from the CORDIAL cohort study.
Alfadda AA; Sherbeeni SM; Alqutub AN; Aldosary AS; Aldaghri NM; Taylor-Robinson SD; Alqahtani SA; Gul R; Almaghamsi AM
Saudi J Gastroenterol; 2022; 28(6):426-433. PubMed ID: 35645140
[TBL] [Abstract][Full Text] [Related]
8. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
[TBL] [Abstract][Full Text] [Related]
9. Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan.
Tuong TTK; Tran DK; Phu PQT; Hong TND; Dinh TC; Chu DT
Diagnostics (Basel); 2020 Mar; 10(3):. PubMed ID: 32183383
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of non-alcoholic fatty liver disease (NAFLD) in a cohort of patients with type 2 diabetes: the PHIGNA-DM2 study.
Martínez-Ortega AJ; Piñar Gutiérrez A; Lara-Romero C; Remón Ruiz PJ; Ampuero-Herrojo J; de Lara-Rodríguez I; Romero-Gómez M; García Luna PP; Soto-Moreno A
Nutr Hosp; 2022 Oct; 39(5):1012-1018. PubMed ID: 36134588
[TBL] [Abstract][Full Text] [Related]
11. Hepatic Steatosis and Fibrosis in Type 2 Diabetes: A Risk-Based Approach to Targeted Screening.
Poustchi H; Alaei-Shahmiri F; Aghili R; Nobarani S; Malek M; Khamseh ME
Arch Iran Med; 2021 Mar; 24(3):177-186. PubMed ID: 33878875
[TBL] [Abstract][Full Text] [Related]
12. The prevalence of nonalcoholic fatty liver disease in Chinese adults screened by vibration controlled transient elastography and its diagnostic discrepancy compared with ultrasound.
Ding Y; Jiang L; Wang Q; Zhao W; Zhou X; Lu J; Tian T; Yu C; Xu X; Guo W; Zhang Q; Song C
Clin Res Hepatol Gastroenterol; 2022 Oct; 46(8):101951. PubMed ID: 35605893
[TBL] [Abstract][Full Text] [Related]
13. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
[TBL] [Abstract][Full Text] [Related]
14. Liver Involvement in Patients with Systemic Sclerosis: Role of Transient Elastography in the Assessment of Hepatic Fibrosis and Steatosis.
Cuomo G; Iandoli C; Galiero R; Caturano A; Di Vico C; Perretta D; Adamo PV; Ferrara R; Rinaldi L; Romano C; Sasso FC
Diagnostics (Basel); 2023 May; 13(10):. PubMed ID: 37238250
[No Abstract] [Full Text] [Related]
15. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes.
Ajmera V; Cepin S; Tesfai K; Hofflich H; Cadman K; Lopez S; Madamba E; Bettencourt R; Richards L; Behling C; Sirlin CB; Loomba R
J Hepatol; 2023 Mar; 78(3):471-478. PubMed ID: 36410554
[TBL] [Abstract][Full Text] [Related]
16. Liver Stiffness Evaluation by Transient Elastography in Type 2 Diabetes Mellitus Patients with Ultrasound-proven Steatosis.
Sporea I; Mare R; Lupușoru R; Sima A; Sirli R; Popescu A; Timar R
J Gastrointestin Liver Dis; 2016 Jun; 25(2):167-74. PubMed ID: 27308647
[TBL] [Abstract][Full Text] [Related]
17. Screening for Liver Steatosis and Fibrosis in Patients with Inflammatory Bowel Disease Using Vibration Controlled Transient Elastography with Controlled Attenuation Parameter.
Trifan A; Stafie R; Rotaru A; Stratina E; Zenovia S; Nastasa R; Huiban L; Cuciureanu T; Muzica C; Chiriac S; Girleanu I; Singeap AM; Sfarti C; Cojocariu C; Petrea O; Stanciu C
J Clin Med; 2022 Oct; 11(19):. PubMed ID: 36233826
[TBL] [Abstract][Full Text] [Related]
18. Vibration Controlled Transient Elastography in Screening for Silent Liver Diseases.
Said E; Abdel-Gawad M; Abdelsameea E; Elshemy EE; Abdeen N; Elbasiony M; Omran D; Elesnawy Y; Eid A; Lashen SA; Elbahr O; Naguib GG; Afify S; Bahbah EI; Alboraie M
Eur J Gastroenterol Hepatol; 2023 Oct; 35(10):1204-1210. PubMed ID: 37577784
[TBL] [Abstract][Full Text] [Related]
19. Accuracy of FibroTouch in assessing liver steatosis and fibrosis in patients with metabolic-associated fatty liver disease combined with type 2 diabetes mellitus.
Yu H; Liu H; Zhang J; Jia G; Yang L; Zhang Q; Li G; Liu F; Di F; Wang F
Ann Palliat Med; 2021 Sep; 10(9):9702-9714. PubMed ID: 34628896
[TBL] [Abstract][Full Text] [Related]
20. Visceral Adipose Tissue and Non-alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes.
Nobarani S; Alaei-Shahmiri F; Aghili R; Malek M; Poustchi H; Lahouti M; Khamseh ME
Dig Dis Sci; 2022 Apr; 67(4):1389-1398. PubMed ID: 33788095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
